The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Five-year follow-up of olutasidenib for IDH1-mutated R/R AML
Jorge Cortes, MD, Georgia Cancer Center Augusta University, Augusta, GA, discusses the use of olutasidenib for IDH1-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML), commenting on the final five-year results from the Phase II pivotal cohort (NCT02719574). This long-term follow-up confirms the value of the agent in treating this patient population, as responses were durable, and no new safety signals were reported. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Olutasidenib is an IDH1 inhibitor. And we had reported the results on patients that had refractory or relapsed AML with of course, with an IDH1 mutation. And what we’re showing now is the five year follow up. And it just confirms the value of this drug. The response rate has not changed. It showed that there is a over 30% response rate. Most of these responses, by the way, are CR, not CRh’s...
Olutasidenib is an IDH1 inhibitor. And we had reported the results on patients that had refractory or relapsed AML with of course, with an IDH1 mutation. And what we’re showing now is the five year follow up. And it just confirms the value of this drug. The response rate has not changed. It showed that there is a over 30% response rate. Most of these responses, by the way, are CR, not CRh’s. There’s a couple of CRh’s, but most are CR’s. But the important thing about the five year is one confirming the durability of the response, where many patients continue receiving the olutasidenib and also the very good overall survival. And these are valuable things because the remission duration was over two years, which is very good in this context. And also the safety profile, we have not seen any more problems long term. For example, early on the signals were differentiation syndrome. But at this point you don’t see anymore, importantly, liver function test abnormalities. We don’t see them. There’s very little signal about QTc prolongation with a longer follow up that remains very, very manageable. So I think overall it just consolidates the value of this drug in this setting.
Read more...
